Cathay Biotech Inc
SSE:688065
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
This alert will be permanently deleted.
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| CN |
C
|
Cathay Biotech Inc
SSE:688065
|
42.2B CNY |
Loading...
|
|
| US |
|
Sherwin-Williams Co
NYSE:SHW
|
87.8B USD |
Loading...
|
|
| US |
|
Ecolab Inc
NYSE:ECL
|
79.8B USD |
Loading...
|
|
| JP |
|
Shin-Etsu Chemical Co Ltd
TSE:4063
|
9.6T JPY |
Loading...
|
|
| CN |
|
Wanhua Chemical Group Co Ltd
SSE:600309
|
275B CNY |
Loading...
|
|
| CH |
|
Givaudan SA
SIX:GIVN
|
27.5B CHF |
Loading...
|
|
| DK |
|
Novozymes A/S
CSE:NZYM B
|
165.6B DKK |
Loading...
|
|
| US |
|
PPG Industries Inc
NYSE:PPG
|
25.8B USD |
Loading...
|
|
| IN |
|
Asian Paints Ltd
NSE:ASIANPAINT
|
2.3T INR |
Loading...
|
|
| CH |
|
Sika AG
F:SIKA
|
19.9B EUR |
Loading...
|
|
| CH |
D
|
DSM-Firmenich AG
AEX:DSFIR
|
17.5B EUR |
Loading...
|
Market Distribution
| Min | -409 046.1% |
| 30th Percentile | -1.4% |
| Median | 4.2% |
| 70th Percentile | 10.3% |
| Max | 876.4% |
Other Profitability Ratios
Cathay Biotech Inc
Glance View
Cathay Biotech Inc. emerged from China's bustling metropolis of Shanghai, carving a niche in the realm of synthetic biology. Born in the late 1990s, the company set its sights on transforming the industrial landscape by harnessing the power of biomanufacturing. Cathay positioned itself as a leader in the production of long-chain diacid (LCDA) and bio-based polyamides, which are integral to a wide array of industries, including automotive, consumer electronics, and textiles. The company's core technology lies in advanced fermentation processes, where microorganisms are bioprocessed to produce these high-performance materials. These procedures not only reduce dependency on petrochemicals but also showcase the potential for sustainable innovations in industrial applications. Cathay Biotech monetizes its expertise by serving as a vital supplier for manufacturers worldwide, tapping into its patented technologies and scaling them to meet commercial demands. Its commitment to R&D has not only propelled the firm’s growth but also established long-term partnerships with key players across various sectors. Through its production facilities, Cathay has managed to fine-tune its microorganism strains and fermentation processes, leading to increased efficiencies and cost-effectiveness. This symbiotic relationship between innovation and commercialization at Cathay Biotech has allowed it to create a robust business model, drawing significant revenue from the sale of its bio-based products while consistently investing in technological advancements to expand its product portfolio.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for Cathay Biotech Inc is 14.2%, which is above its 3-year median of 13.5%.
Over the last 3 years, Cathay Biotech Inc’s Operating Margin has decreased from 19.1% to 14.2%. During this period, it reached a low of 11.6% on Dec 31, 2023 and a high of 19.1% on Sep 30, 2022.